{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:06:03Z","timestamp":1780513563691,"version":"3.54.1"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.blre.2019.100650","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T11:22:08Z","timestamp":1576840928000},"page":"100650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The minimal that kills: Why defining and targeting measurable residual disease is the \u201cSine Qua Non\u201d for further progress in management of acute myeloid leukemia"],"prefix":"10.1016","volume":"43","author":[{"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwal C.","family":"Boddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Halene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.100650_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.3","article-title":"Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life","volume":"6","author":"Bower","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2019.100650_bb0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100650_bb0015","first-page":"1","article-title":"Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?","author":"Bewersdorf","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.100650_bb0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0025","series-title":"SEER Cancer Statistics Review, 1975\u20132016","author":"Howlader","year":"2017"},{"key":"10.1016\/j.blre.2019.100650_bb0030","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1200\/JCO.2017.72.7149","article-title":"Health care use by older adults with acute myeloid leukemia at the end of life","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0035","series-title":"SEER Cancer Statistics Review, 1975-2015","author":"Noone","year":"2017"},{"key":"10.1016\/j.blre.2019.100650_bb0040","series-title":"SEER Cancer Statistics Review, 1975\u20132015","author":"Noone","year":"2017"},{"key":"10.1016\/j.blre.2019.100650_bb0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2017.285","article-title":"Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0050","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0055","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0060","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/asheducation-2016.1.356","article-title":"MRD in AML: does it already guide therapy decision-making?","volume":"2016","author":"Ossenkoppele","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2019.100650_bb0070","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","article-title":"Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d?","volume":"124","author":"Grimwade","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0075","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1200\/JCO.2011.41.5323","article-title":"Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia","volume":"30","author":"Inaba","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0080","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular Minimal Residual Disease in Acute Myeloid Leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100650_bb0085","series-title":"NCCN guidelines version 1.2019: Chronic Myeloid Leukemia","author":"Network NCC","year":"2019"},{"key":"10.1016\/j.blre.2019.100650_bb0090","series-title":"NCCN guidelines version 1.2019: Acute Lymphoblastic Leukemia","author":"Network NCC","year":"2019"},{"key":"10.1016\/j.blre.2019.100650_bb0095","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0100","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0686-1","article-title":"Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience","volume":"12","author":"Chamoun","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0115","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0120","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaoncol.2017.2009","article-title":"Minimal residual disease in chronic lymphocytic Leukemia in the era of novel agents: a Review","volume":"4","author":"Thompson","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0125","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2016-05-714162","article-title":"Minimal residual disease is an independent predictor for 10-year survival in CLL","volume":"128","author":"Kwok","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"Bottcher","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0135","series-title":"NCCN guidelines version 4.2019: Chronic Lymphocytic Leukemia\/Small Lymphocytic Leukemia","author":"Network NCC","year":"2019"},{"key":"10.1016\/j.blre.2019.100650_bb0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0145","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.clml.2017.02.019","article-title":"Minimal residual disease assessment and risk-based therapy in acute lymphoblastic leukemia","volume":"17s","author":"Bassan","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.blre.2019.100650_bb0150","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0155","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0160","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.100650_bb0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/16078454.2019.1567654","article-title":"Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia","volume":"24","author":"G\u00f6kbuget","year":"2019","journal-title":"Hematology."},{"key":"10.1016\/j.blre.2019.100650_bb0170","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0175","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0180","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0190","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0195","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/s41375-018-0219-5","article-title":"Molecular remission as a therapeutic objective in acute promyelocytic leukemia","volume":"32","author":"Cicconi","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0200","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V92.3.784","volume":"92","author":"Diverio","year":"1998","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0205","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/0140-6736(92)92625-P","article-title":"Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia","volume":"340","author":"Lo Coco","year":"1992","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2019.100650_bb0210","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1073\/pnas.89.7.2694","article-title":"Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia","volume":"89","author":"Miller","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100650_bb0215","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V88.4.1390.bloodjournal8841390","article-title":"AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto (GIMEMA) pilot study","volume":"88","author":"Avvisati","year":"1996","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100650_bb0225","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0230","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/sj.leu.2404501","article-title":"Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention","volume":"21","author":"Esteve","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0235","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1182\/blood.V94.7.2225.419k03_2225_2229","article-title":"Therapy of molecular relapse in acute promyelocytic leukemia","volume":"94","author":"Lo Coco","year":"1999","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0240","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/leu.2015.12","article-title":"Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet","volume":"29","author":"Lengfelder","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0245","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/leu.2016.122","article-title":"PML\u2013RAR\u03b1 kinetics and impact of FLT3\u2013ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy","volume":"30","author":"Cicconi","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0250","series-title":"NCCN guidelines version 2.2019: Acute Myeloid Leukemia","author":"Network NCC","year":"2019"},{"key":"10.1016\/j.blre.2019.100650_bb0255","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2016.09.006","article-title":"Monitoring minimal residual disease in acute leukemia: technical challenges and interpretive complexities","volume":"31","author":"Chen","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100650_bb0260","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11899-018-0479-1","article-title":"Minimal\/measurable residual disease detection in acute leukemias by multiparameter flow cytometry","volume":"13","author":"Fuda","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2019.100650_bb0265","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1096-8652(199808)58:4<278::AID-AJH5>3.0.CO;2-N","article-title":"Biologic and clinical significance of CD7 expression in acute myeloid leukemia","volume":"58","author":"Saxena","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100650_bb0270","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1309\/FY0UMAMM91VPMR2W","article-title":"Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry","volume":"129","author":"Al-Mawali","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2019.100650_bb0275","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood.V97.11.3574","article-title":"High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)","volume":"97","author":"Baer","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0280","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/blood-2016-02-695312","article-title":"Evolution of acute myelogenous leukemia stem cell properties after treatment and progression","volume":"128","author":"Ho","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0285","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2015.255","article-title":"Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia","volume":"30","author":"Zeijlemaker","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0290","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/leu.2014.327","article-title":"Prognostic value of monitoring a candidate immunophenotypic leukaemic stem\/progenitor cell population in patients allografted for acute myeloid leukaemia","volume":"29","author":"Bradbury","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0295","doi-asserted-by":"crossref","first-page":"e107587","DOI":"10.1371\/journal.pone.0107587","article-title":"Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia","volume":"9","author":"Terwijn","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100650_bb0300","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/10428190701817266","article-title":"A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse","volume":"49","author":"Lane","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.100650_bb0305","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0310","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.2010.28.6468","article-title":"Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia","volume":"28","author":"Corbacioglu","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0315","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kronke","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0320","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0325","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0330","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100650_bb0335","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100650_bb0340","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1600-0609.2011.01673.x","article-title":"NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression","volume":"87","author":"Kristensen","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2019.100650_bb0345","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3109\/10428194.2013.840776","article-title":"Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse","volume":"55","author":"Jain","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.100650_bb0350","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/bloodadvances.2018023432","article-title":"NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse","volume":"2","author":"Hollein","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.100650_bb0355","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia","volume":"122","author":"Kr\u00f6nke","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2015.02.006","article-title":"Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation","volume":"43","author":"Stahl","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2019.100650_bb0365","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR","volume":"17","author":"Drandi","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.blre.2019.100650_bb0370","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.13038","article-title":"Quantification of rare NPM1 mutation subtypes by digital PCR","volume":"167","author":"Bacher","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100650_bb0375","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1182\/bloodadvances.2018020222","article-title":"Clinical consequences of clonal hematopoiesis of indeterminate potential","volume":"2","author":"Steensma","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.blre.2019.100650_bb0380","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0385","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100650_bb0390","doi-asserted-by":"crossref","first-page":"100587","DOI":"10.1016\/j.blre.2019.100587","article-title":"From clonal hematopoiesis to myeloid leukemia and what happens in between: will improved understanding lead to new therapeutic and preventive opportunities?","volume":"37","author":"Bewersdorf","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100650_bb0395","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2019.100650_bb0400","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0405","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2019.100650_bb0410","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2019.100650_bb0415","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jmoldx.2012.08.001","article-title":"Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data","volume":"15","author":"Spencer","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.blre.2019.100650_bb0420","doi-asserted-by":"crossref","first-page":"22812","DOI":"10.18632\/oncotarget.4333","article-title":"Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia","volume":"6","author":"Bibault","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.blre.2019.100650_bb0425","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2019.100650_bb0430","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.blre.2019.100650_bb0435","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nmeth.3351","article-title":"Sequencing small genomic targets with high efficiency and extreme accuracy","volume":"12","author":"Schmitt","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.blre.2019.100650_bb0440","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100650_bb0445","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100650_bb0450","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0455","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0460","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.beha.2019.05.003","article-title":"Can we incorporate MRD assessment into clinical practice in AML?","volume":"32","author":"Ossenkoppele","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2019.100650_bb0465","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0470","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100650_bb0475","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0480","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid Leukemia with NPM1 mutation: A Study by the Acute Leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0485","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid Leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0490","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid Leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0495","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0500","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0505","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbmt.2015.10.024","article-title":"Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-Cytometric evidence of leukemia in acute myeloid leukemia","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.100650_bb0510","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1200\/JCO.2007.15.9814","article-title":"Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia","volume":"26","author":"Maurillo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0515","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0520","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2019.100650_bb0525","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.blre.2019.100650_bb0530","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/j.bbmt.2019.01.016","article-title":"Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Zeiser","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.100650_bb0535","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1182\/blood-2007-02-072470","article-title":"Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia","volume":"109","author":"Dominietto","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0540","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0545","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.blre.2016.09.005","article-title":"Selecting initial treatment of acute myeloid leukaemia in older adults","volume":"31","author":"Podoltsev","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100650_bb0550","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ajh.24782","article-title":"Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia","volume":"92","author":"Ragon","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100650_bb0555","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0560","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0565","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant <em>NPM1<\/em> is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0570","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0575","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/fon.15.326","article-title":"Design of the randomized, Phase III, QUAZAR AML maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia","volume":"12","author":"Roboz","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0580","series-title":"Celgene Announces Phase 3 QUAZAR\u00ae AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints","author":"Celgene","year":"2019"},{"key":"10.1016\/j.blre.2019.100650_bb0585","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2016.252","article-title":"Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)","volume":"31","author":"Blum","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0590","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0595","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose Cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0600","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-019-0133-1","article-title":"Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose","volume":"8","author":"Jilg","year":"2019","journal-title":"Exp Hematol."},{"key":"10.1016\/j.blre.2019.100650_bb0605","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2019.100650_bb0610","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2019.100650_bb0615","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100650_bb0620","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0625","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0630","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2018-99-113582","article-title":"Radius: A Phase 2 randomized trial investigating standard of care \u00b1 midostaurin after allogeneic stem cell transplant in FLT3-ITD-mutated AML","volume":"132","author":"Maziarz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100650_bb0635","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2018-99-112614","article-title":"Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre sormain trial","volume":"132","author":"Burchert","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100650_bb0640","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100650_bb0645","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clml.2014.12.005","article-title":"Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid Leukemia after allogeneic hematopoietic cell transplantation","volume":"15","author":"Antar","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2019.100650_bb0650","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/pbc.25437","article-title":"Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3\/ITD acute myeloid leukemia","volume":"62","author":"Tarlock","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"Suppl","key":"10.1016\/j.blre.2019.100650_bb0655","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.blre.2019.100650_bb0660","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0665","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood.V128.22.2900.2900","article-title":"Defining the immune checkpoint landscape in patients (pts) with acute myeloid leukemia (AML)","author":"Daver","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100650_bb0670","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2019.100650_bb0675","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","article-title":"The emerging role of immune checkpoint based approaches in AML and MDS","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.100650_bb0680","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood-2004-01-0064","article-title":"In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis","volume":"104","author":"Saudemont","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100650_bb0685","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","article-title":"Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era?","volume":"34","author":"Liu","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100650_bb0690","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","author":"Laszlo","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0695","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell\u2013engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0700","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2018-05-849802","article-title":"Bifunctional PD-1 x alphaCD3 x alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia","volume":"132","author":"Herrmann","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0705","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0710","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","article-title":"Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia","volume":"34","author":"Morsink","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100650_bb0715","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0720","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/ijms18112259","article-title":"Development of a chimeric antigen receptor targeting C-type l-like molecule-1 for human acute myeloid leukemia","volume":"18","author":"Laborda","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2019.100650_bb0725","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V126.23.325.325","article-title":"Preclinical evaluation of MCLA117, a CLEC12AxCD3 Bispecific antibody efficiently targeting a novel leukemic stem cell associated antigen in AML","volume":"126","author":"Van Loo","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0730","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3324\/haematol.2009.009811","article-title":"Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia","volume":"95","author":"Zhao","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2019.100650_bb0735","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.blre.2019.100650_bb0740","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Al-Hussaini","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0745","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/leu.2014.128","article-title":"Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC","volume":"28","author":"Busfield","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0750","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.3324\/haematol.2015.135467","article-title":"Droplet digital polymerase chain reaction for DNMT3A and IDH1\/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"Brambati","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2019.100650_bb0755","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3324\/haematol.2018.194712","article-title":"A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia","volume":"104","author":"Onecha","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2019.100650_bb0760","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","article-title":"Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?","volume":"34","author":"Liu","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100650_bb0765","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2017-11-785873","article-title":"Vaccine therapy in hematologic malignancies","volume":"131","author":"Avigan","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0770","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100650_bb0775","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.18632\/oncotarget.2196","article-title":"MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin","volume":"5","author":"Lambert","year":"2014","journal-title":"Oncotarget."},{"key":"10.1016\/j.blre.2019.100650_bb0780","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.9","article-title":"Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML","volume":"49","author":"Anthias","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.100650_bb0785","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3324\/haematol.2015.131946","article-title":"Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial","volume":"101","author":"Willekens","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2019.100650_bb0790","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/sj.leu.2404659","article-title":"The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors","volume":"21","author":"Weisser","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2019.100650_bb0795","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.V128.22.1207.1207","article-title":"Minimal residual disease monitoring in acute myeloid leukemia (AML) with translocation t(8;21)(q22;q22): results of the AML Study Group (AMLSG)","volume":"128","author":"Agrawal","year":"2016","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1930164X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1930164X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:24:21Z","timestamp":1759436661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X1930164X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":159,"alternative-id":["S0268960X1930164X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.100650","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The minimal that kills: Why defining and targeting measurable residual disease is the \u201cSine Qua Non\u201d for further progress in management of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.100650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100650"}}